Aim Several biomarkers are currently used as diagnostic and prognostic tools in patients with cancer. Soluble urokinase plasminogen activator receptor (suPAR) is elevated in acute and chronic inflammatory procedures and several observational studies during the last 20 years have investigated its role in oncology. The purpose of this article was to review the current literature regarding suPAR’s role in clinical practice. Methods A systematic literature search of PubMed, Scopus, OpenGrey and Cochrane Library databases through September 2021 was conducted using the following search terms: “supar” or “soluble urokinase plasminogen receptor” and “cancer” or “malignancy”. Original articles reporting on suPAR’s role in the diagnosis, prognosis and prediction of therapeutic outcomes in patients with confirmed or suspected cancer were included. Results Among 45 found articles, the most were observational cohort studies. The included studies were further categorized by cancer site. SuPAR level was higher in patients with cancer compared to healthy controls, but its diagnostic and prognostic accuracy differs depending on the site of cancer. Conclusion SuPAR has promising aspects in the field of oncology and public health and future research should further investigate its use in clinical practice. As it is elevated in different types of cancer, it could potentially serve as an adjunctive tool for the mass screening of patients with non-specific signs of cancer, but larger cohort studies that support these findings must be conducted.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. p. 209–49.
2.
David M, Leslie S. Prostate Specific Antigen. StatPearls [Internet]. Treasure Island (FL. StatPearls Publishing; 2021.
3.
Henry N, Hayes D. Cancer biomarkers. Mol Oncol. 2012. p. 140–6.
4.
Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G, et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer. 2011. p. 448.
5.
Aronen A, Aittoniemi J, Huttunen R, Nikkola A, Rinta-Kiikka I, Nikkola J, et al. Plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer. Scand J Gastroenterol. 2021. p. 81–5.
6.
Rasmussen L, Schultz M, Iversen K, Olsen E, Helms J, David M, et al. Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer. Clin Biochem. 2020. p. 31–7.
7.
Loosen S, Gorgulho J, Jördens M, Schulze-Hagen M, Beier F, Vucur M, et al. Serum levels of soluble urokinase plasminogen activator receptor predict tumor response and outcome to immune checkpoint inhibitor therapy. Front Oncol. 2021. p. 646883.
8.
Gao W, Wang Z, Bai X, Xi X, Ruan C. Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients. Thromb Res. 2001. p. 25–31.
9.
Rasmussen L, Schultz M, Gaardsting A, Ladelund S, Garred P, Iversen K, et al. Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. Int J Cancer. 2017. p. 191–9.
10.
Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen T, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010. p. 296–308.
11.
Özdirik B, Stueven A, Knorr J, Geisler L, Mohr R, Demir M, et al. Soluble urokinase plasminogen activator receptor (suPAR) concentrations are elevated in patients with neuroendocrine malignancies. J Clin Med. 2020. p. 1647.
12.
Wach S, Al-Janabi O, Weigelt K, Fischer K, Greither T, Marcou M, et al. Taubert H. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. Int J Cancer. 2015. p. 1406–16.
13.
Mccabe N, Angwafo F, Zaher A, Selman S, Kouinche A, Jankun J. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep. 2000. p. 879–82.
14.
Piironen T, Haese A, Huland H, Steuber T, Christensen I, Brünner N, et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Che. 2006. p. 838–44.
15.
Steuber T, Vickers A, Haese A, Kattan M, Eastham J, Scardino P, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer. 2007. p. 1499–504.
16.
Shariat S, Roehrborn C, Mcconnell J, Park S, Alam N, Wheeler T, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007. p. 349–55.
17.
Taubert AJO, Lohse-Fischer H, Fröhner A, Wach M, Stöhr S, Keck R, et al. Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer. Biomed Res Int. 2014. p. 972587.
18.
Kjellman A, Akre O, Gustafsson O, Høyer-Hansen G, Lilja H, Norming U, et al. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening. J Intern Med. 2011. p. 299–305.
19.
Liu K, Luo J, Wu J, Wang Y, Fan H. A preliminary study of the value of plasma microrna-193b and soluble urokinase-type plasminogen activator receptor in identifying patients with early-stage colorectal cancer and. Clin Lab. 2017. p. 1949–53.
20.
Usnarska-Zubkiewicz L, Strutyńska-Karpińska M, Zubkiewicz-Kucharska A, Zarębski P, Grabowski K. Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report. Adv Clin Exp Med. 2014. p. 959–67.
21.
Fidan E, Mentese A, Ozdemir F, Deger O, Kavgaci H, Karahan C, et al. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med Oncol. 2013. p. 540.
22.
Lomholt A, Høyer-Hansen G, Nielsen H. Christensen IJ. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer. 2009. p. 992–7.
23.
Loosen S, Tacke F, Binnebosel M, Leyh C, Vucur M, Heitkamp F, et al. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases. Oncotarget. 2018. p. 27027–38.
24.
Lomholt A, Christensen I, Høyer-Hansen G, Nielsen H. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol. 2010. p. 805–11.
25.
Fernebro E, Madsen R, Fernö M, Brünner N, Bendahl P, Christensen I, et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer. 2001. p. 486–91.
26.
Riisbro R, Christensen I, Nielsen H, Brünner N, Nilbert M, Fernebro E. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers. 2005. p. 93–102.
27.
Høgdall C, Christensen I, Stephens R, Sørensen S, Nørgaard-Pedersen B, Nielsen H. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma su-PAR, plasma PAI-1 and serum CEA. APMIS. 2002. p. 630–8.
28.
Tarpgaard L, Christensen I, Høyer-Hansen G, Lund I, Guren T, Glimelius B, et al. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. Int J Cancer. 2015. p. 2470–7.
29.
Rolff H, Christensen I, Svendsen L, Wilhelmsen M, Lund I, Thurison T, et al. The concentration of the cleaved suPAR forms in pre-and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study. J Surg Oncol. 2019. p. 1404–11.
30.
Chounta A, Ellinas C, Tzanetakou V, Pliarhopoulou F, Mplani V, Oikonomou A, et al. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. Liver Int. 2015. p. 601–7.
31.
Loosen S, Schulze-Hagen M, Vucur M, Gorgulho J, Paffenholz P, Benz F, et al. Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis. JGH Open. 2021. p. 356–63.
32.
Loosen S, Breuer A, Tacke F, Kather J, Gorgulho J, Alizai P, et al. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer. JHEP Rep. 2020. p. 100080.
33.
Loosen S, Tacke F, Püthe N, Binneboesel M, Wiltberger G, Alizai P, et al. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. Carcinogenesis. 2019. p. 947–55.
34.
Langkilde A, Hansen T, Ladelund S, Linneberg A, Andersen O, Haugaard S, et al. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancerfree individuals. Cancer Epidemiol Biomarkers Prev. 2011. p. 609–18.
35.
Yalcin S, Demir M, Ozturk R, Kılınç A, Suer H, Karahan I. Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer. Pteridines. 2020. p. 136–41.
36.
Riisbro R, Christensen I, Piironen T, Greenall M, Larsen B, Stephens R, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res. 2002. p. 1132–41.
37.
Nijziel M, Van Oerle R, Hellenbrand D, Van Pampus E, Hillen H, Hamulyák K. The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease. J Thromb Haemost. 2003. p. 982–6.
38.
Leandersson P, Kalapotharakos G, Henic E, Borgfeldt H, Petzold M, Høyer-Hansen G, et al. A Biomarker panel increases the diagnostic performance for epithelial ovarian cancer type I and II in young women. Anticancer Res. 2016. p. 957–65.
39.
Henic E, Borgfeldt C, Christensen I, Casslén B, Høyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res. 2008. p. 5785–93.
40.
Begum F, Høgdall C, Kjaer S, Christensen L, Blaakaer J, Bock J, et al. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res. 2004. p. 1981–5.
41.
Begum F, Høgdall E, Riisbro R, Christensen I, Engelholm S, Jørgensen M, et al. Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC). APMIS. 2006. p. 675–81.
42.
Ljuca D, Fatusić Z, Iljazović E, Ahmetović B. Monitoring of chemotherapy successfulness of platina/ taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn J Basic Med Sci. 2007. p. 111–6.
43.
Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015. p. 492.
44.
Riisbro R, Stephens R, Brünner N, Christensen I, Nielsen H, Heilmann L, et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol. 2001. p. 523–31.
45.
Shen J, Wang Q, Wang J, Su G, Wang J, Guo S, et al. Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis. Oncol Lett. 2015. p. 2403–9.
46.
Erkut N, Menteşe A, Özbaş H, Ermantaş N, Sümer A, Örem A, et al. The prognostic significance of soluble urokinase plasminogen activator receptor in acute myeloid leukemia. Turk J Haematol. 2016. p. 135–40.
47.
Guo H, Zhou L, Ma H, Liu B, Cheng J, Ma Y, et al. Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia. Oncol Lett. 2017. p. 383–9.
48.
Fujimura K, Ebinuma H, Fukamachi I, Ohwada C, Kawaguchi T, Shimizu N, et al. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin’s lymphoma. Clin Chim Acta. 2014. p. 48–54.
49.
De Bock C, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004. p. 13–39.
50.
Eugen-Olsen J, Giamarellos-Bourboulis E, Supar. The unspecific marker for disease presence, severity and prognosis. Int J Antimicrob Agents. 2015. p. 33–4.
51.
Thunø M, Macho B, Eugen-Olsen J, Supar. the molecular crystal ball. Dis Markers. 2009. p. 157–72.
52.
Frankenne F, Noel A, Bajou K, Sounni N, Goffin F, Masson V, et al. Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy. Emerging Therapeutic Targets. 1999. p. 469–81.
53.
Liu K, Fan J, Wu J. Prognostic role of circulating soluble uPAR in various cancers: a systematic review and meta-analysis. Clin Lab. 2017.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
